The effects of vaginal bromocriptine and dienogest on women with adenomyosis: a clinical study

In: Middle East Fertility Society Journal · 2024 · vol. 29(1) · doi:10.1186/s43043-024-00213-6 · W4405713483
article OA: diamond CC0
📄 Open PDF View on OpenAlex View at publisher

Abstract

Abstract Objective Adenomyosis occurs when endometrial glands and stroma develop in the myometrium, leading to symptoms such as pelvic pain and heavy menstrual bleeding. Method This randomized, double-blinded, controlled trial study was conducted on patients with adenomyosis referred to the Rasul-e-Akram Hospital. Group A received vaginal bromocriptine, and group B received dienogest. Transvaginal ultrasonography (TVS), visual analog scale (VAS), and pictorial blood loss assessment chart (PBLAC) evaluation were performed at the beginning and after 3, 6, and 9 months of the study. Result The mean blood visual chart 3 and 6 months after intervention in the bromocriptine group was significantly lower than the dienogest group ( P < 0.001). The mean intensity of menstrual pain 3 months after intervention was significantly lower in the dienogest group compared to the bromocriptine group ( P < 0.001). There was a significant improvement in TVS appearance in both groups at the 6-month follow-up. Conclusion Dienogest and bromocriptine both effectively reduced pain intensity, menstrual bleeding, and sonographic characteristics in patients with adenomyosis.

My notes (saved in your browser only)

Outcome instruments

VAS-pain MUSA

Condition tags

adenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (19)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK